News

Aurisco Pharmaceutical has announced that its manufacturing site in Yangzhou, China, has successfully passed a U.S. Food and Drug Administration (FDA) inspection. The company said the…
Read More...

Alfasigma S.p.A. has agreed to acquire Nordic Pharma, a specialty pharmaceutical company with operations across Europe, Canada and Japan, in a move that will expand Alfasigma’s…
Read More...

Eli Lilly and Company has filed six new lawsuits against U.S. entities accused of selling unauthorized retatrutide products, escalating the pharmaceutical company's efforts to combat…
Read More...

Summit Therapeutics has announced that its partner Akeso has received marketing authorization from China’s National Medical Products Administration (NMPA) for ivonescimab in combination…
Read More...

Sentynl Therapeutics, a U.S.-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, has entered into an option and license agreement with clinical-stage rare…
Read More...

Infinimmune, a biotechnology company developing fully human antibody therapeutics derived directly from the human immune system, has raised $75 million in a Series A financing round to…
Read More...

Remepy, a biotechnology company developing a new class of medicines that combine prescription drugs with personalized, AI-driven therapeutic applications, has raised $36 million in a…
Read More...

Epicrispr Biotechnologies, a clinical-stage biotechnology company developing programmable epigenetic medicines, has raised $90 million in an oversubscribed Series C financing round to…
Read More...

Swedish pharmaceutical company Sobi and Innate Pharma have entered into a strategic partnership to advance lacutamab, an investigational treatment for cutaneous T-cell lymphoma (CTCL),…
Read More...

Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a deal worth up to $1.32 billion, adding an experimental precision medicine for a rare form of epilepsy to…
Read More...

Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement that will give Innovent sole commercialization rights for Vanflyta (quizartinib) in China, expanding the Chinese…
Read More...

Revolution Medicines and BeOne Medicines are joining forces to test new drug combinations aimed at cancers driven by RAS mutations, while also expanding access to Revolution Medicines’…
Read More...

Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku to advance ENERGI-F703DFU, an experimental topical treatment being developed for diabetic foot…
Read More...

FUJIFILM Corporation and Taiho Pharmaceutical have formed a strategic partnership to advance manufacturing technologies for next-generation antibody-drug conjugates (ADCs), aiming to…
Read More...

Amplia Therapeutics has entered into a clinical trial collaboration with Eli Lilly and Company to evaluate a new targeted treatment combination for patients with advanced non-small cell…
Read More...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the…
Read More...

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in a tax-free, all-stock merger of equals that will create a leading biopharmaceutical company focused on…
Read More...

Curium and Lantheus have announced a definitive agreement to combine their businesses in a deal valued at up to approximately $8 billion, creating one of the world's largest…
Read More...

Ratio Therapeutics has secured $70 million in Series C financing to accelerate the development of its radiopharmaceutical pipeline, advance clinical trials, and expand its manufacturing…
Read More...

IMPACT Therapeutics has signed an exclusive licensing agreement with global specialty pharmaceutical company Pharmanovia to expand the reach of its ovarian cancer treatment, senaparib,…
Read More...